On April 27, 2026 TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, reported the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 29ᵗʰ Annual Meeting being held May 11 – 15 in Boston, MA as well as virtually.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation Details:
Title: Novel CD45-targeted TCR-T cell therapies designed to eliminate residual disease and prevent relapse following allogeneic hematopoietic cell transplantation
Authors: Hannah L Bader, Kostadin P Petrov, Stephen Carroll, Debanjan Goswamy, Nivya Sharma, Shubhangi Kamalia, Daniel Pollacksmith, Drashti Sha, Kenneth L Jahan, Ryan E Kritzer, Hana Husic, Shobhita Jillella, Nicole Ladd, Jackson Lirette, Shoshana Bloom, Prachi Dhanania, Lisa Fleischer, Chandan K Pavuluri, Tyler M Sinacola, Savannah G Szemethy, McKenna A Merrill, Kyra N Sur, Carolyn Hardy, Zhonghua Zhu, Elisaveta Todorova, Alexander Cristofaro, Livio Dukaj, Kimberly M Cirelli, Antoine Boudot, Mollie M Jurewicz, Cagan Gurer
Abstract ID: 1256
Session Date/Time: Tuesday, May 12; Poster Reception: 5:00 – 6:30 p.m. Eastern Time
Location: Poster Hall, Thomas M. Menino Convention & Exhibition Center
Once the presentation has concluded, a copy of the materials will be added to the "Publications" section of the Company’s website at tscan.com.
(Press release, TScan Therapeutics, APR 27, 2026, View Source [SID1234664833])